Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS
April 02 2024 - 4:30PM
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on
reducing the risk of stroke and its devastating impact, today
announced the launch of its ENROUTE
® Transcarotid
Neuroprotection System PLUS (“NPS PLUS”), a key component of the
TCAR® portfolio. This next generation device builds upon the prior
ENROUTE Transcarotid Neuroprotection System to deliver smoother
arterial sheath insertion, greater flow precision, and a simplified
prep experience for surgical teams, all while maintaining
unparalleled neuroprotection during the TCAR procedure.
“With the launch of the NPS PLUS, we're thrilled to empower our
TCAR-trained physicians with a solution that addresses their
insights and feedback to further strengthen and streamline the TCAR
procedure,” shared Chas McKhann, Chief Executive Officer of Silk
Road Medical. “Our focus on new product innovation reflects our
ongoing commitment to leadership in the treatment of carotid
disease.”
TCAR combines direct carotid artery access with robust blood
flow reversal, providing neuroprotection akin to open surgical
techniques in a less invasive, more patient-friendly approach to
treating carotid artery disease. During TCAR, the surgical team
inserts a tube-like sheath into the carotid artery and connects it
to the ENROUTE Neuroprotection System, which temporarily reverses
blood flow. The system filters potentially dangerous debris from
the blood to reduce intraprocedural stroke risk while the team uses
a TCAR-specific balloon and stent to open the artery and contain
the carotid artery disease. TCAR delivers less than 1%
periprocedural stroke rates and a better patient recovery
experience than open surgery.
“Silk Road Medical's responsiveness to our feedback has provided
us with better procedure predictability and a more streamlined
workflow for our entire surgical team," remarked Brian Peterson,
MD, FACS, FSVS of St. Luke’s Heart and Vascular Institute. "With
over 500 TCAR procedures performed by our team, we view TCAR as a
first-line treatment option for carotid disease and we’re excited
about what these improvements mean for patient care.”
Click here for more information on the ENROUTE Neuroprotection
System PLUS.
About TCAR with the ENROUTE Transcarotid
Neuroprotection and Stent SystemTCAR (Transcarotid Artery
Revascularization) is a clinically proven procedure combining
surgical principles of neuroprotection with minimally invasive
endovascular techniques to treat blockages in the carotid artery at
risk of causing a stroke. The ENROUTE Transcarotid Stent is
intended to be used in patients at high risk and standard risk for
complications from CEA, in conjunction with the ENROUTE
Transcarotid Neuroprotection System (NPS) during the TCAR
procedure. The ENROUTE Transcarotid NPS is a first in class device
used to directly access the common carotid artery and initiate
high-rate temporary blood flow reversal to protect the brain from
stroke while delivering and implanting the ENROUTE Transcarotid
Stent.
About Silk Road Medical Silk Road Medical,
Inc. (NASDAQ: SILK), is a medical device company with
locations in Sunnyvale, California, and Plymouth, Minnesota,
that is focused on reducing the risk of stroke and its devastating
impact. The company has pioneered a new approach for the treatment
of carotid artery disease called Transcarotid Artery
Revascularization (TCAR). TCAR is a clinically proven procedure
combining surgical principles of neuroprotection with minimally
invasive endovascular techniques to treat blockages in the carotid
artery at risk of causing a stroke. For more information on how
Silk Road Medical is delivering brighter patient outcomes through
brighter thinking, visit www.silkroadmed.com and connect on
Twitter, LinkedIn and Facebook.
Investors:Marissa BychGilmartin
Groupinvestors@silkroadmed.com |
Media:Michael FanucchiSilk Road
Medicalmfanucchi@silkroadmed.com |
|
|
Silk Road Medical (NASDAQ:SILK)
Historical Stock Chart
From Sep 2024 to Oct 2024
Silk Road Medical (NASDAQ:SILK)
Historical Stock Chart
From Oct 2023 to Oct 2024